Almirall H1 2026 Results

Source Summary

BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its financial results for the first half of 2026. The company delivered solid H1 2026 results, with Net Sales growing 7.5% YoY to €602.7 MM and EBITDA increasing 23.7% YoY to €150.7 MM. The results are in line with Almirall’s long-term growth trajectory, and the company reiterated its full-year 2026 guidance of 9-12% Net Sales growth and EBITDA of €270 MM to